NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...

Amivantamab plus chemotherapy delivered promising OS trends compared with chemotherapy in EGFR-mutant advanced non-small cell ...

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

For patients with early breast cancer, hypofractionated radiation was noninferior to normofractionated radiation regarding ...

Patients with early-stage triple-negative breast cancer tended to have improved survival with neoadjuvant pembrolizumab plus ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

Study findings support tivozanib monotherapy for second-line treatment of certain patients with metastatic RCC, an expert ...

Experts discuss the adverse events observed with talquetamab, including oral toxicities and skin and nail issues, and how these are managed.

Panelists discuss how chronic graft-versus-host disease (cGVHD) differs from acute GVHD, its main challenges for patients, and its common symptoms and impact on daily life.